PURPOSE: @entity1398 ( @entity1398 ) after chemotherapy increases complications, morbidity, risk of @entity204 , reduction of dose delivery and impairs quality of life. Primary @entity1261 ( @entity1261 ) prophylaxis after chemotherapy is recommended in the guideline (GL) if the risk of @entity1398 is high (>= 20  %) or intermediate (>= 10-20  %) with additional risk factors. This study evaluated the implementation of @entity1261 GL. @entity1 AND METHODS: Sample size of the survey was calculated at 2  % of the incidences of @entity706 , @entity0 in Germany in 2006. @entity1 were documented retrospectively over three to nine cycles of chemotherapy and @entity1398 risk >= 10  %. Professional physician profiles were analyzed by classification and regression tree analysis (CART). RESULTS: One hundred ninety-five hematologists-oncologists and pulmonologists and gynecologists specialized in oncology documented data of 666 @entity2 @entity1 , 286 @entity706 @entity1 , and 976 @entity0 @entity1 , with 7805 chemotherapy cycles; 85.1  % of physicians claimed adhering to @entity1261 GL. Adherence to GL in all high- @entity1398 -risk chemotherapy cycles was 15.4  % in @entity2 , 84.5  % in @entity706 , and 85.6  % in @entity0 , and in all intermediate- @entity1398 -risk chemotherapy cycles, @entity2 it was 38.8  %, @entity706 it was 59.4  %, and @entity0 it was 49.3  %. @entity1261 was overused without additional @entity1 risk factors in 7.2  % @entity2 cycles, 16.8  % @entity706 cycles, and 17.6  % @entity0 cycles. The CART analysis split pulmonologists and other specialists, with the latter adhering more to GL. Pulmonologists, trained less than 22.5  years, adhered better to GL, as did also gynecologists or hematologists-oncologists with professional experience less than 8.1  years. CONCLUSIONS: Acceptance of and adherence to @entity1261 GL differed between @entity2 , @entity706 , and @entity0 . Physicians overestimate their adherence to the GL. Physicians adhering to the GL can be characterized.

Adherence to @entity1261 ( @entity1261 ) guidelines to reduce the incidence of XXXX after chemotherapy-a representative sample survey in Germany.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'malignant lymphoma'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer, and lung cancer', 'breast cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['FN', 'Febrile neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1398 :: (MESH:D009503,Disease) :: ['febrile neutropenia']
